Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2024-01-12 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and details changes in issued share capital and share buybacks for Ocumension Therapeutics. It includes specific data on repurchases of shares, dates, quantities, prices, and confirmations that these transactions comply with listing rules on the Stock Exchange of Hong Kong. The content focuses on share repurchase activities and capital changes rather than financial results, management changes, or regulatory certifications. The document is lengthy (over 12,000 characters) and contains detailed transactional data, not just an announcement or summary. Therefore, it fits the category of a report on share repurchases and capital changes, which corresponds to the 'Transaction in Own Shares' category (POS).
2024-01-12 English
Next Day Disclosure Return (Resubmission)
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ocumension Therapeutics. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It fits the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length is over 10,000 characters and contains substantive data on share repurchases, confirming it is not merely an announcement or certification but a detailed transaction report.
2024-01-11 English
Next Day Disclosure Return (Resubmission)
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return filed by Ocumension Therapeutics, detailing changes in issued share capital and share buybacks. It includes specific data on repurchases of shares, dates, prices, and confirmations that these repurchases comply with listing rules. The document references Main Board Listing Rules and GEM Listing Rules of the Hong Kong Stock Exchange. It is a regulatory disclosure about share repurchases, not a full financial report or earnings release. The content fits the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length (10,510 characters) and detailed transactional data support this classification rather than a brief announcement or a general regulatory filing.
2024-01-11 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ocumension Therapeutics. It details repurchases of shares, exercises of share options, and confirmations related to compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on share capital changes and repurchase activities, with no financial statements or earnings data. This matches the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2024-01-10 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and details changes in issued share capital and share buybacks for Ocumension Therapeutics. It includes specific data on repurchases of shares, exercises of share options, and confirmations related to compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on share capital changes and repurchase activities rather than financial results, management changes, or other report types. This matches the description of a 'Transaction in Own Shares' filing, which reports the company's buyback or sale of its own shares. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the appropriate classification is 'POS' (Transaction in Own Shares).
2024-01-09 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ocumension Therapeutics. It details repurchases of shares, exercises of share options, and confirmations related to share capital changes. The document references compliance with listing rules of the Stock Exchange of Hong Kong and provides detailed transactional data on share repurchases and issuances. This type of document is a regulatory disclosure about share capital changes and share buybacks, which fits the category of Transaction in Own Shares (POS). It is not an announcement of a report, nor a full financial report, but a detailed disclosure of share transactions by the company itself. Therefore, the correct classification is POS.
2024-01-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.